Multiple Sclerosis (MS) is the most common autoimmune demyelinating disorder that affects the central nervous system.
MS affects predominantly young adults in the prime of their lives. NeuroTheryX is developing novel orally available small
molecule therapeutics for the treatment of multiple sclerosis and other diseases of the central nervous system.
The lead molecule has demonstrated efficacy in a mouse model of MS. BioTheryX, Inc.
(www.biotheryx.com) is a majority shareholder of NeuroTheryX.
Please stay tuned for more to come.